Fidaxomicin - Merck
Alternative Names: Dafclir; Dificid; Dificlir; Difimicin; Lipiarmycin; OPT-80; PAR-101; Tiacumicin-BLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Optimer Pharmaceuticals
- Developer Astellas Pharma; Merck & Co; Optimer Pharmaceuticals; Tillotts Pharma
- Class Antibacterials; Glycosides; Macrocyclic compounds; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Clostridium difficile infections
- Discontinued Methicillin-resistant Staphylococcus aureus infections